Amarin Corp Plc (AMRN)

[ziploc_1]

Nsleven...In 2018, Amarin and Mochida inked an agreement to"collaborate" on new EPA meds...

"Among other terms in the agreement, Amarin obtained an exclusive license to certain Mochida intellectual property to advance Amarin’s interests in
the United States and certain other territories and the parties will Collaborate to research and develop NEW products and INDICATIONS based on EPA for
Amarin’s commercialization in the United States and certain other territories. The potential new product and indication opportunities contemplated under this agreement are in relatively EARLY stages of development."

This 2018 PR does not indicate..
-what the "new" products are?

It is of interest that Amarin chose to commit $100 Thousand to a Mochida study of MND-2119 that started on 2022 and is slated to end in Q4 2024.


It is interesting that Amarin committed $100
-is one of the "new" products RMND-2119?
-will royalties need to paid by Amarin to Mochida for commercialization of RMND-2199?
-Are there any royalty payments due to either party in connection with the med, LR-EtEPA...which Amarin recently patented?